A Dual‐Channel Synergistic Ultrasensitive Biosensor for Tumor Liquid Biopsy
Advanced Science · 2026
DOI: 10.1002/advs.75443 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Yu Sun und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Peking University Third Hospital, Beijing, P. R. China. Hauptthemen laut MEDLINE: Biosensing Techniques, Circulating Tumor DNA, Glioma, Brain Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Liquid biopsy technology, which detects circulating tumor DNA (ctDNA) in cerebrospinal fluid, plays a crucial role in the early diagnosis and precision treatment of gliomas. However, the intrinsically low abundance and rapid clearance of ctDNA pose substantial challenges for conventional analytical techniques, such as droplet digital PCR and next‐generation sequencing. Here, we introduce a label‐free dual‐channel synergistic detection strategy that enables quantitative analysis of ctDNA at the zeptomolar level. Leveraging a synergistic design that includes structural symmetry breaking and momentum condition regulation, the optical platform overcomes the inherent structural field confinement and enhances the effectiveness of target‐contacted sensing. By integrating a DNA tetrahedron‐hybridization chain reaction‐gold nanoparticle cascade amplification system, the dual‐channel synergistic biosensor achieves an ultra‐low detection limit of 74 zM while covering a dynamic range spanning 12 orders of magnitude. Clinical validation has confirmed that this dual‐channel synergistic detection strategy can accurately identify the IDH1.R132H mutation in glioma patients with as little as 1 µL of sample, and deliver crucial clinical information such as tumor size and staging. This label‐free, rapid, cost‐effective, and highly sensitive biosensing platform offers a powerful tool for early cancer screening, molecular diagnostics, and longitudinal disease monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Peking University Third Hospital, Beijing, P. R. China.
- Department of Intensive Care Unit, Peking University Third Hospital, Beijing, P. R. China.
- Innovation Laboratory of Terahertz Biophysics, National Innovation Institute of Defense Technology, Beijing, P. R. China.
- Air and Missile Defense College, Air Force Engineering University, Xi'an, P. R. China.
- Department of Otorhinolaryngology, Head and Neck Surgery, The Sixth Medical Center of the Chinese PLA General Hospital, Beijing, P. R. China.
- Center for Precision Neurosurgery and Oncology of Peking University Health Science Center, Beijing, P. R. China.
ORCID-Profile: Jun Yang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Sun, Y., Zhang, J., Liu, C., Lou, J., Wang, S., Ji, X., Zhao, X., Xu, S., Feng, J., Liu, B., Chang, C., Ge, Q., & Yang, J. (2026). A Dual‐Channel Synergistic Ultrasensitive Biosensor for Tumor Liquid Biopsy. Advanced Science. https://doi.org/10.1002/advs.75443
Vancouver
Sun Y, Zhang J, Liu C, Lou J, Wang S, Ji X, et al. A Dual‐Channel Synergistic Ultrasensitive Biosensor for Tumor Liquid Biopsy. Advanced Science. 2026. doi:10.1002/advs.75443
BibTeX
@article{Sun2026,
author = {Sun, Yu and Zhang, Jing and Liu, Chenqing and Lou, Jing and Wang, Sihui and Ji, Xiangtian and Zhao, Xiaofang and Xu, Shirui and Feng, Jingyu and Liu, Bin and Chang, Chao and Ge, Qinggang and Yang, Jun},
title = {A Dual‐Channel Synergistic Ultrasensitive Biosensor for Tumor Liquid Biopsy},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.75443}
}
EUVIMED